IMUX News and Press, Immunic Inc.

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium PR Newswire – Patent Covers Label-Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 – ...

Immunic to Participate in Investor Conferences in March PR Newswire NEW YORK , March 3, 2026 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal dis...

2026-02-26 06:44:05 ET More on Immunic Immunic rises after $400M private placement, leadership transition Seeking Alpha’s Quant Rating on Immunic Historical earnings data for Immunic Financial information for Immunic Read the full article on ...

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update PR Newswire – Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 – – Raised Proceeds of $200 Million i...

Immunic Announces Closing of Oversubscribed Private Placement Financing PR Newswire – Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – – Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing M...

2026-02-13 10:04:10 ET In biotechnology, few milestones carry more weight than securing the capital required to cross the finish line. As clinical-stage companies approach pivotal trials and potential commercialization, access to substantial funding can dramatically reshape both timelines a...

2026-02-13 09:30:48 ET Immunic, Inc. (NASDAQ:IMUX) shares surged 20% in Friday morning trading following the announcement of a significant oversubscribed private placement. This financing deal positions the company to raise up to $400 million, capital that will directly fund its advance...

2026-02-13 09:19:16 ET Denver, Colorado- Innovation-focused names are setting the tone this morning, with capital flows clustering around companies showing clear execution milestones, commercial inflection points, and technical breakouts. Iveda Expands into Europe and the Chart Is Res...

2026-02-13 08:46:37 ET More on Immunic Seeking Alpha’s Quant Rating on Immunic Historical earnings data for Immunic Financial information for Immunic Read the full article on Seeking Alpha For further details see: Immunic rises after $400M ...

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company PR Newswire – Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – – Expe...